Firstly, CALR-mutated patients, regardless of age group, started therapy with the JAK2 inhibitor with a more severe clinical burden characterized by more frequent anemia, higher blast percentages, and higher presence of high-risk biological features including increased marrow fibrosis and presence of HMR mutations. Here, JAK2 is linked to anemia (phenotype).